Additional data from the ongoing Phase 2b ORIGIN clinical trial to be presented in the second half of 2023 and 2024; Expect to announce preliminary data from the pivotal ORIGIN 3 trial in the first half of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERA:
- Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
- Vera Therapeutics announces efficacy, safety results Phase 2b ORIGIN trial
- Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
- Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN